NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

PCVX

Vaxcyte Inc

Apr 17 • 04:00PM ET

30.65

Dollar change +1.53
Percentage change 5.25	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX NVAX AZN JNJ GSK ALNY NVCR VNDA

| Held by: VTI VB IWM VXF VBK XBI IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.88	Insider Own	2.89%	Shs Outstand	128.76M	Perf Week	9.31%
Market Cap	3.95B	Forward P/E	-	EPS next Y	-4.60	Insider Trans	-4.61%	Shs Float	125.04M	Perf Month	-59.75%
Income	-463.93M	PEG	-	EPS next Q	-1.05	Inst Own	108.16%	Short Float	9.63%	Perf Quarter	-65.10%
Sales	0.00M	P/S	-	EPS this Y	-18.91%	Inst Trans	3.97%	Short Ratio	6.12	Perf Half Y	-73.46%
Book/sh	26.47	P/B	1.16	EPS next Y	-1.86%	ROA	-18.78%	Short Interest	12.05M	Perf Year	-50.76%
Cash/sh	13.57	P/C	2.26	EPS next 5Y	-4.74%	ROE	-20.41%	52W Range	27.66 - 121.06	Perf YTD	-62.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-29.88%	ROI	-13.76%	52W High	-74.68%	Beta	1.35
Dividend TTM	-	Quick Ratio	12.75	Sales past 5Y	0.00%	Gross Margin	-	52W Low	10.81%	ATR (14)	4.28
Dividend Ex-Date	-	Current Ratio	12.75	EPS Y/Y TTM	7.75%	Oper. Margin	-	RSI (14)	26.64	Volatility	8.41% 9.95%
Employees	414	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	129.50
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	42.11%	Payout	-	Rel Volume	0.88	Prev Close	29.12
Sales Surprise	-	EPS Surprise	7.82%	Sales Q/Q	-	Earnings	Feb 25 AMC	Avg Volume	1.97M	Price	30.65
SMA20	-29.52%	SMA50	-52.22%	SMA200	-64.46%	Trades		Volume	1,724,212	Change	5.25%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Initiated	Goldman	Buy	$135
Dec-07-23	Initiated	Mizuho	Buy	$69
Apr-18-23	Initiated	TD Cowen	Outperform
Jan-03-23	Reiterated	Needham	Buy	$52 → $58
Dec-15-22	Initiated	Guggenheim	Buy	$66
Nov-17-22	Initiated	BTIG Research	Buy	$69
Dec-29-21	Resumed	Jefferies	Buy	$50
Jun-24-21	Resumed	Jefferies	Buy	$50
Jul-07-20	Initiated	Needham	Buy	$40
Jul-07-20	Initiated	Cantor Fitzgerald	Overweight	$55
Jul-07-20	Initiated	BofA Securities	Buy	$37

Show Previous Ratings

Apr-11-25 04:21PM	Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller's Top Stock Pick with Huge Upside Potential (Insider Monkey) +11.27%
Apr-10-25 01:07PM	Vaxcyte Stock Plummets 56% in a Month: Here's the Reason (Zacks) -8.96%
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Apr-01-25 12:45PM	Vaxcyte narrow misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI (TipRanks) -14.65%
12:16PM	Loading…
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
07:19AM	Vaxcyte stock sinks despite Phase II IPD vaccine trial success (Clinical Trials Arena)
Mar-31-25 05:20PM	Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (Seeking Alpha) -45.64%
04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily)
03:39PM	Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (Seeking Alpha)
09:57AM	Moderna, biotech stocks slide on resignation of FDA official Peter Marks (Yahoo Finance)
09:57AM	Moderna, biotech stocks slide following resignation of FDA official Peter Marks (Yahoo Finance)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
07:00AM	Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
06:30PM	Loading…
Mar-30-25 06:30PM	Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now (Insider Monkey)
05:00PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study (GlobeNewswire)
04:08PM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 11:34AM	Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive (Zacks)
09:44AM	Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? (InsiderMonkey)
Mar-25-25 08:02AM	Vaxcyte (PCVX) Struggled Amid Political Uncertainty (InsiderMonkey)
Mar-20-25 12:00PM	Lazard US Equity Concentrated Portfolio Q4 2024 Commentary (SeekingAlpha)
Mar-07-25 05:35AM	Goldman Sachs Says Its Time to Pull the Trigger on Healthcare Stocks Here Are 2 Names to Pounce on Now (TipRanks)
Mar-03-25 06:50PM	Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now (Insider Monkey)
Feb-26-25 11:03AM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds (Insider Monkey)
07:26AM	Q4 2024 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM	Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Financial Health and Promising ... (GuruFocus.com)
Feb-25-25 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
12:30PM	Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily)
04:05PM	Loading…
Feb-12-25 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (GlobeNewswire)
01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-08-25 09:22AM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-06-25 08:20AM	Vaxcyte advances second stage of Phase 2 study evaluating VAX-31 (TipRanks)
07:22AM	Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants (Clinical Trials Arena)
Feb-05-25 08:00AM	Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Jan-30-25 04:05PM	Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-18-25 05:50PM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts? (Insider Monkey)
Dec-23-24 10:11AM	Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-09-24 07:57AM	What Makes Vaxcyte (PCVX) An Investment Bet? (Insider Monkey)
Dec-04-24 10:03AM	Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants (Clinical Trials Arena)
Dec-03-24 08:00AM	Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Nov-27-24 09:29AM	Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug (Insider Monkey)
Nov-12-24 07:30AM	Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs (GlobeNewswire)
Nov-06-24 12:09AM	Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight (GuruFocus.com)
Nov-05-24 04:01PM	Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-24 09:13AM	Should You Consider Investing in Vaxcyte (PCVX)? (Insider Monkey)
Sep-14-24 07:47PM	Vaxcyte, Inc. (PCVX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-11-24 04:05PM	Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 04:05PM	Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Obesity drug startup raises $67M; Vors shielded transplant shows promise (BioPharma Dive)
Sep-04-24 11:58PM	Vaxcyte Announces Pricing of $1.3 Billion Public Offering (GlobeNewswire)
Sep-03-24 06:06PM	Vaccine Maker Raising $1 Billion Leads Post-Holiday Share Sales (Bloomberg) +36.39%
04:09PM	Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market (Investor's Business Daily)
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
01:22PM	Heard on the Street: Pfizer Better Watch Out for This Biotech (The Wall Street Journal)
11:43AM	Biotech Startup Vaxcyte Is a Threat to Pfizer and Merck. A Vaccine Candidate Is Why. (Barrons.com)
10:48AM	Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data. (Barrons.com)
09:40AM	Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher (Benzinga)
09:07AM	Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market (Investor's Business Daily)
08:10AM	Vaxcytes best-case data for pneumococcal vaccine boost shares (BioPharma Dive)
07:07AM	Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Sep-02-24 06:40PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Aug-06-24 04:05PM	Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 07:02PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
Jul-31-24 09:55AM	Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? (Zacks)
Jul-29-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice (Zacks)
Jul-02-24 07:01PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
08:30AM	Vaxcyte Appoints John Furey to Board of Directors (GlobeNewswire)
May-10-24 12:32PM	Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview (GuruFocus.com)
May-08-24 10:55PM	PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-04-24 02:31AM	Insider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)
Apr-22-24 04:46PM	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing (MT Newswires)
Apr-02-24 04:05PM	Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 09:02PM	Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances (GuruFocus.com)
Mar-20-24 07:01PM	Insider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-04-24 08:30AM	Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants (GlobeNewswire)
Feb-28-24 12:08PM	Q4 2023 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents) -7.33%
12:00PM	Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know (Zacks)
09:57AM	Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-24 08:32AM	Why Vaxcyte (PCVX) Might Surprise This Earnings Season (Zacks)
Feb-25-24 11:05AM	5 Best Russell 2000 Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-22-24 11:28PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares (GuruFocus.com)
Feb-15-24 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (GlobeNewswire)
Feb-02-24 11:12PM	Director Heath Lukatch Sells 5,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
06:39PM	Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-01-24 11:02PM	Director Heath Lukatch Sells 4,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com) +5.75%
04:05PM	Vaxcyte to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-30-24 11:37PM	Vaxcyte Announces Pricing of $750 Million Public Offering (GlobeNewswire) +6.04%
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-29-24 08:30AM	Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older (GlobeNewswire) +6.52%
Jan-19-24 08:28PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Jan-16-24 04:01PM	Vaxcyte Appoints Whitney Jones as Chief People Officer (GlobeNewswire)
Jan-04-24 04:01PM	Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise (GlobeNewswire) -7.07%
Dec-21-23 05:01PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares (GuruFocus.com)
Dec-04-23 06:35PM	VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate (GlobeNewswire)
Nov-28-23 08:30AM	Vaxcyte Appoints Jacks Lee to Board of Directors (GlobeNewswire)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lukatch Heath	Director	Apr 08 '25	Option Exercise	16.78	7,000	117,490	14,175	Apr 10 08:06 AM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 07 '25	Option Exercise	20.93	4,777	99,983	131,950	Apr 09 08:05 AM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 04 '25	Option Exercise	8.96	20,533	183,888	518,775	Apr 07 07:38 AM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 05 '25	Option Exercise	21.41	5,000	107,050	46,620	Mar 07 04:43 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 05 '25	Sale	70.74	5,000	353,699	41,620	Mar 07 04:43 PM
Eydelman Mikhail	Officer	Mar 05 '25	Proposed Sale	68.87	5,000	344,350		Mar 05 04:10 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 03 '25	Option Exercise	4.38	8,000	35,071	162,931	Mar 03 09:14 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 03 '25	Sale	73.27	8,000	586,165	154,931	Mar 03 09:14 PM
Wassil Jim	Officer	Mar 03 '25	Proposed Sale	73.17	8,000	585,360		Mar 03 04:06 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 18 '25	Option Exercise	5.35	8,000	42,800	117,491	Feb 19 06:04 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 18 '25	Sale	83.85	8,000	670,823	109,491	Feb 19 06:04 PM
GUGGENHIME ANDREW	Officer	Feb 18 '25	Proposed Sale	102.08	8,000	816,640		Feb 18 04:29 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 05 '25	Option Exercise	21.41	5,000	107,050	33,222	Feb 07 04:04 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 05 '25	Sale	90.07	5,000	450,369	28,222	Feb 07 04:04 PM
Eydelman Mikhail	Officer	Feb 05 '25	Proposed Sale	87.53	5,000	437,650		Feb 05 04:01 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 03 '25	Option Exercise	2.42	8,000	19,360	213,695	Feb 04 07:20 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 03 '25	Sale	86.22	8,000	689,790	205,695	Feb 04 07:20 PM
Wassil Jim	Officer	Feb 03 '25	Proposed Sale	88.20	8,000	705,600		Feb 03 04:05 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 21 '25	Option Exercise	5.35	8,000	42,800	117,491	Jan 22 06:18 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 21 '25	Sale	86.51	8,000	692,101	109,491	Jan 22 06:18 PM
GUGGENHIME ANDREW	Officer	Jan 21 '25	Proposed Sale	86.06	8,000	688,480		Jan 21 04:04 PM
Loxam Teri	Director	Jan 15 '25	Option Exercise	22.70	6,250	141,875	13,425	Jan 17 04:05 PM
Loxam Teri	Director	Jan 15 '25	Sale	85.11	6,250	531,963	7,175	Jan 17 04:05 PM
Loxam Teri	Director	Jan 15 '25	Proposed Sale	80.32	6,250	502,000		Jan 15 04:04 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jan 06 '25	Option Exercise	21.41	5,000	107,050	33,222	Jan 07 04:33 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jan 06 '25	Sale	85.58	5,000	427,923	28,222	Jan 07 04:33 PM
Eydelman Mikhail	Officer	Jan 06 '25	Proposed Sale	84.23	5,000	421,150		Jan 06 04:02 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jan 02 '25	Option Exercise	2.42	8,000	19,360	213,695	Jan 03 06:07 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jan 02 '25	Sale	83.66	8,000	669,267	205,695	Jan 03 06:07 PM
Wassil Jim	Officer	Jan 02 '25	Proposed Sale	82.64	8,000	661,120		Jan 02 04:10 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Dec 18 '24	Option Exercise	5.35	8,000	42,800	117,491	Dec 19 04:07 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Dec 18 '24	Sale	88.78	8,000	710,249	109,491	Dec 19 04:07 PM
Cowan Elvia	SVP, FINANCE	Dec 16 '24	Option Exercise	25.92	7,716	199,999	19,294	Dec 18 04:13 PM
GUGGENHIME ANDREW	Officer	Dec 18 '24	Proposed Sale	89.83	8,000	718,640		Dec 18 04:03 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Dec 09 '24	Sale	92.25	2,366	218,253	136,215	Dec 10 04:10 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Dec 05 '24	Option Exercise	21.41	5,000	107,050	33,697	Dec 09 06:28 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Dec 05 '24	Sale	91.49	5,000	457,434	28,697	Dec 09 06:28 PM
PICKERING GRANT	Officer	Dec 09 '24	Proposed Sale	93.68	2,366	221,647		Dec 09 04:07 PM
Eydelman Mikhail	Officer	Dec 05 '24	Proposed Sale	92.75	5,000	463,750		Dec 05 04:04 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Dec 02 '24	Sale	92.45	15,000	1,386,794	450,301	Dec 03 07:15 PM
Wassil Jim	CHIEF OPERATING OFFICER	Dec 02 '24	Option Exercise	2.42	8,000	19,360	213,695	Dec 03 07:13 PM
Wassil Jim	CHIEF OPERATING OFFICER	Dec 02 '24	Sale	92.49	8,000	739,885	205,695	Dec 03 07:13 PM
Wassil Jim	Officer	Dec 02 '24	Proposed Sale	94.01	8,000	752,080		Dec 02 04:07 PM
PICKERING GRANT	Officer	Dec 02 '24	Proposed Sale	94.01	15,000	1,410,150		Dec 02 04:04 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Nov 18 '24	Option Exercise	5.35	8,000	42,800	117,491	Nov 19 04:43 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Nov 18 '24	Sale	85.81	8,000	686,518	109,491	Nov 19 04:43 PM
GUGGENHIME ANDREW	Officer	Nov 18 '24	Proposed Sale	86.50	8,000	692,000		Nov 18 04:02 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Nov 07 '24	Option Exercise	3.71	30,792	114,308	466,011	Nov 08 08:46 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Nov 07 '24	Sale	103.89	2,366	245,796	137,398	Nov 08 08:46 PM
PICKERING GRANT	Officer	Nov 07 '24	Proposed Sale	104.08	2,366	246,253		Nov 07 04:13 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Nov 05 '24	Option Exercise	21.41	5,000	107,050	33,623	Nov 06 04:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Nov 05 '24	Sale	106.36	5,000	531,803	28,623	Nov 06 04:15 PM
Eydelman Mikhail	Officer	Nov 05 '24	Proposed Sale	105.18	5,000	525,900		Nov 05 04:08 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Nov 01 '24	Sale	106.82	15,000	1,602,252	435,219	Nov 04 06:46 PM
Wassil Jim	CHIEF OPERATING OFFICER	Nov 01 '24	Option Exercise	2.42	8,000	19,360	213,695	Nov 04 06:45 PM
Wassil Jim	CHIEF OPERATING OFFICER	Nov 01 '24	Sale	106.80	8,000	854,423	205,695	Nov 04 06:45 PM
PICKERING GRANT	Officer	Nov 01 '24	Proposed Sale	106.76	15,000	1,601,400		Nov 01 04:04 PM
Wassil Jim	Officer	Nov 01 '24	Proposed Sale	106.76	8,000	854,080		Nov 01 04:02 PM
Wassil Jim	CHIEF OPERATING OFFICER	Oct 28 '24	Option Exercise	16.04	5,049	80,981	205,695	Oct 29 07:41 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Oct 25 '24	Option Exercise	20.93	19,108	399,930	109,491	Oct 28 05:11 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Oct 18 '24	Option Exercise	5.35	42,000	224,700	132,383	Oct 22 04:11 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Oct 18 '24	Sale	115.39	42,000	4,846,508	90,383	Oct 22 04:11 PM
GUGGENHIME ANDREW	Officer	Oct 18 '24	Proposed Sale	115.88	42,000	4,866,960		Oct 18 04:02 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Oct 07 '24	Sale	109.21	7,098	775,154	138,581	Oct 08 08:32 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Oct 07 '24	Option Exercise	21.41	5,000	107,050	33,623	Oct 08 08:29 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Oct 07 '24	Sale	109.27	5,000	546,353	28,623	Oct 08 08:29 PM
PICKERING GRANT	Officer	Oct 07 '24	Proposed Sale	111.12	7,098	788,730		Oct 07 04:12 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Oct 01 '24	Option Exercise	5.35	40,000	214,000	470,219	Oct 03 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Oct 01 '24	Sale	114.25	55,000	6,283,861	450,219	Oct 03 04:17 PM
Wassil Jim	CHIEF OPERATING OFFICER	Oct 01 '24	Option Exercise	2.42	8,000	19,360	208,646	Oct 03 04:16 PM
Wassil Jim	CHIEF OPERATING OFFICER	Oct 01 '24	Sale	114.24	8,000	913,917	200,646	Oct 03 04:16 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Oct 01 '24	Option Exercise	21.41	5,500	117,755	34,123	Oct 03 04:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Oct 01 '24	Sale	114.24	5,500	628,295	28,623	Oct 03 04:15 PM
PICKERING GRANT	Officer	Oct 01 '24	Proposed Sale	114.55	55,000	6,300,250		Oct 01 04:04 PM
Eydelman Mikhail	Officer	Oct 01 '24	Proposed Sale	114.55	5,500	630,025		Oct 01 04:04 PM
Wassil Jim	Officer	Oct 01 '24	Proposed Sale	114.55	8,000	916,400		Oct 01 04:04 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Sep 18 '24	Option Exercise	5.35	8,000	42,800	98,383	Sep 19 05:48 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Sep 18 '24	Sale	115.94	8,000	927,551	90,383	Sep 19 05:48 PM
Loxam Teri	Director	Sep 17 '24	Option Exercise	22.70	6,250	141,875	13,425	Sep 18 04:24 PM
Loxam Teri	Director	Sep 17 '24	Sale	116.28	6,250	726,731	7,175	Sep 18 04:24 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 16 '24	Option Exercise	2.42	10,000	24,200	211,958	Sep 18 04:23 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 16 '24	Sale	115.96	10,000	1,159,635	200,646	Sep 18 04:23 PM
GUGGENHIME ANDREW	Officer	Sep 18 '24	Proposed Sale	116.75	8,000	934,000		Sep 18 04:11 PM
Loxam Teri	Director	Sep 17 '24	Proposed Sale	113.93	6,250	712,062		Sep 17 04:11 PM
Wassil Jim	Officer	Sep 16 '24	Proposed Sale	115.90	10,000	1,159,000		Sep 16 04:17 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 03 '24	Option Exercise	2.42	10,000	24,200	217,503	Sep 05 05:19 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 03 '24	Sale	111.93	10,000	1,119,252	207,503	Sep 05 05:19 PM
Cowan Elvia	SVP, FINANCE	Sep 03 '24	Option Exercise	25.92	5,000	129,600	17,723	Sep 05 05:15 PM
Cowan Elvia	SVP, FINANCE	Sep 03 '24	Sale	107.67	5,000	538,350	12,723	Sep 05 05:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Sep 03 '24	Option Exercise	21.41	1,667	35,690	32,493	Sep 05 05:13 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Sep 03 '24	Sale	112.11	1,667	186,880	30,826	Sep 05 05:13 PM
Cowan Elvia	Officer	Sep 03 '24	Proposed Sale	107.67	5,000	538,350		Sep 03 04:08 PM
Wassil Jim	Officer	Sep 03 '24	Proposed Sale	107.67	10,000	1,076,700		Sep 03 04:07 PM
Eydelman Mikhail	Officer	Sep 03 '24	Proposed Sale	107.67	1,667	179,485		Sep 03 04:04 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 23 '24	Option Exercise	2.03	15,000	30,450	493,888	Aug 26 04:58 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 23 '24	Sale	78.98	15,000	1,184,767	478,888	Aug 26 04:58 PM
PICKERING GRANT	Officer	Aug 23 '24	Proposed Sale	78.89	15,000	1,183,350		Aug 23 04:03 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Aug 19 '24	Option Exercise	5.35	8,000	42,800	104,720	Aug 20 04:49 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Aug 19 '24	Sale	78.58	8,000	628,650	96,720	Aug 20 04:49 PM
GUGGENHIME ANDREW	Officer	Aug 19 '24	Proposed Sale	78.91	8,000	631,280		Aug 19 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PCVX

Vaxcyte Inc

Upgrade your FINVIZ experience